UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF
THE SECURITIES EXCHANGE ACT OF 1934
Filed by the Registrant x Filed by a Party other than the Registrant ¨
Check the appropriate box:
| ¨ | Preliminary Proxy Statement | |
| ¨ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | |
| ¨ | Definitive Proxy Statement | |
| x | Definitive Additional Materials | |
| ¨ | Soliciting Material under §240.14a-12 | |
Evoke Pharma, Inc.
(Name of Registrant as Specified in Its Charter)
(Name of Person(s) Filing Proxy Statement, if other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
| x | No fee required. | |||
| ¨ | Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. | |||
| (1) | Title of each class of securities to which transaction applies:
| |||
| (2) | Aggregate number of securities to which transaction applies:
| |||
| (3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
| |||
| (4) | Proposed maximum aggregate value of transaction:
| |||
| (5) | Total fee paid:
| |||
| ¨ | Fee paid previously with preliminary materials. | |||
| ¨ | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. | |||
| (1) | Amount Previously Paid:
| |||
| (2) | Form, Schedule or Registration Statement No.:
| |||
| (3) | Filing Party:
| |||
| (4) | Date Filed:
| |||
EVOKE PHARMA
Important Notice Regarding the
Availability of Proxy Materials for the Shareholder Meeting to be held on April 22, 2015, for Evoke Pharma, Inc. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We
encourage you to access and review all of the important information contained in the proxy materials before voting. To view the proxy statement and annual report, go to www.proxydocs.com/evok. To submit your proxy while visiting this site, you will
need the 12 digit control number in the box below. Under new United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet.
We have chosen to use these procedures for our 2015 Annual Meeting and need YOUR participation. If the you proxy want materials, to receive you a must paper request or e-mail one. copy There of to is no receive charge a paper to you package for
requesting in time a for copy. this In year’s order annual before April meeting, 10, 2015. please make this request on or Proxy Materials Available to View or Receive: 1. Proxy Statement 2. Annual Report Printed materials may be requested by
one of the following methods:
INTERNET TELEPHONE *E-MAIL www.investorelections.com/evok (866) 648 8133 paper@investorelections.com
You must use the 12 digit control number located in the shaded gray box below. If requesting material by e-mail, please send a blank e-mail with the 12 digit control number
(located below) in the subject line. No other requests, instructions or other inquiries should be included with your e-mail requesting material.
ACCOUNT NO. SHARES
EVOKE PHARMA
Company Notice of Annual Meeting
Date:
Wednesday, April 22, 2015
Time:
9:00 a.m. (Local Time)
Place:
12670 High Bluff Drive, San Diego, CA 92130
The purpose of the Annual Meeting is to take action on the following proposals:
The Board of
Directors recommends that you vote “FOR” the following.
1. To elect two (2) directors
Nominees 01 Cam L. Garner
02 Scott L. Glenn
2. Proposal 2: Ratification of the appointment of BDO USA, LLP as our independent registered public accountants for the
year ending December 31, 2015
3. Proposal 3: Transact such other business as may be properly
brought before the meeting or any adjournment or postponement